NASDAQ: ARTLArtelo Biosciences Inc Stock
$1.34+0.03 (+2.29%)
Updated Apr 24, 2024
ARTL Price
$1.34
Fair Value Price
$2.41
Market Cap
$4.33M
52 Week Low
$1.15
52 Week High
$2.98
P/E
-0.43x
P/B
0.37x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.29M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$8M
Beta
0.99
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ARTL Overview
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ARTL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ARTL ($1.34) is undervalued by 44.29% relative to our estimate of its Fair Value price of $2.41 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ARTL ($1.34) is significantly undervalued by 44.29% relative to our estimate of its Fair Value price of $2.41 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ARTL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ARTL due diligence checks available for Premium users.
Be the first to know about important ARTL news, forecast changes, insider trades & much more!
ARTL News
Valuation
ARTL fair value
Fair Value of ARTL stock based on Discounted Cash Flow (DCF)
Price
$1.34
Fair Value
$2.41
Undervalued by
44.38%
ARTL ($1.34) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ARTL ($1.34) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ARTL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ARTL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.43x
Industry
15.69x
Market
41.27x
ARTL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.37x
Industry
5.86x
ARTL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ARTL's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.1M
Profit Margin
0%
ARTL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$13.0M
Liabilities
$1.3M
Debt to equity
0.11
ARTL's short-term assets ($10.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARTL's short-term assets ($10.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARTL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ARTL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.6M
Investing
$2.7M
Financing
$32.0k
ARTL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ARTL vs Biotech Stocks
Artelo Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.